Pulmonary Nodule Follow-Up: A Comprehensive Guide to Ground-Glass Nodule Risk Assessment

Introduction

With the widespread use of low-dose CT screening, more and more people are being diagnosed with pulmonary ground-glass nodules during health check-ups. Faced with the report's mention of "ground-glass opacity," many people's first reaction is panic, worrying that it is a precursor to lung cancer. In fact, approximately 80% of ground-glass nodules are benign or indolent lesions that do not require immediate surgery. However, how to scientifically assess risk and develop a follow-up plan is a common question among international patients. Based on international guidelines, this article breaks down the key points of risk assessment and follow-up management for ground-glass nodules, helping you respond calmly.

What Is a Ground-Glass Nodule? Benign or Malignant?

A ground-glass nodule (GGN) refers to a nodule on CT that shows slightly increased density while bronchial and vascular structures remain visible, resembling frosted glass. It is classified into pure ground-glass nodules and mixed ground-glass nodules (containing solid components).

According to the 2024 guidelines from the Fleischner Society in the United States, the malignancy probability of GGNs is directly related to size and composition:

Pure GGN <6mm: Malignancy probability is less than 1%; follow-up is usually not required.

Pure GGN 6-8mm: Malignancy probability is approximately 2-5%; repeat CT is recommended at 6-12 months.

Pure GGN >8mm: Malignancy probability rises to 10%; follow-up at 3-6 months is needed, with further evaluation considered.

Mixed GGN: The higher the solid component, the greater the risk; when the solid component is >6mm, the malignancy probability can reach 30%.

Importantly, GGNs grow slowly, with an average doubling time of about 800 days, making follow-up a safe approach.

Risk Assessment: Three Dimensions Determine Follow-Up Strategy

1. Nodule Size and Density

Size is the primary indicator. However, in addition to the maximum diameter, attention should also be paid to the mean diameter and volume. In terms of density, pure GGNs carry lower risk than mixed GGNs, where the consolidation-to-tumor ratio (CTR) is an important prognostic factor. A Japanese JCOG study showed that GGNs with a CTR ≤0.25 have a 5-year survival rate close to 100%. Therefore, radiologists will precisely measure the solid component, which directly affects your follow-up frequency.

2. Morphological Features: Margins, Shape, and Internal Structure

Malignant GGNs often present with features such as lobulation, spiculation, pleural indentation, air bronchograms, or vascular convergence. Benign nodules, in contrast, typically have smooth margins and a round shape. However, some early-stage lung cancers can also appear round, so morphology alone is insufficient. It is recommended that you retain each CT image for comparison of changes over time.

3. Growth Rate and Dynamic Changes

The core value of follow-up is to observe changes. If a GGN shows no change at the 6-month follow-up, the interval can be extended; if it enlarges or the solid component increases, vigilance is required. A study published in Lung Cancer indicated that approximately 20% of pure GGNs enlarge during follow-up, and of these, 70% are ultimately invasive adenocarcinomas, but because growth is slow, timely surgery can still be curative.

Follow-Up Plan: How Often Should You Be Rechecked?

Major international guidelines (Fleischner, NCCN) recommend stratified follow-up:

Low risk (pure GGN <6mm): No routine follow-up is needed, but if the patient is anxious, a single repeat scan after 24 months may be considered.

Moderate risk (pure GGN 6-8mm): Initial follow-up at 6-12 months; if no change, repeat every 2 years up to 5 years.

High risk (mixed GGN or >8mm): Initial follow-up at 3-6 months; if stable, annual follow-up for 3-5 years.

For international patients, it is recommended to bring original imaging (in DICOM format) during follow-up in China to facilitate expert comparison. Mei Jia Kang can assist in arranging remote image interpretation by leading radiologists in Shanghai to ensure accurate assessment.

When Is Intervention Needed? Surgery or Continued Observation?

Multidisciplinary consultation and intervention should be considered in the following situations:

Nodule enlargement of ≥2mm per year, or an increase in the solid component.

Solid component ≥8mm in a mixed GGN.

Presence of high-risk factors (age >40, smoking history, family history of lung cancer).

Intervention options include CT-guided needle biopsy or video-assisted thoracoscopic wedge resection. For indolent early-stage lung cancer, sublobar resection can achieve a cure, with a 5-year survival rate exceeding 95%. However, many patients are anxious about surgery, yet modern minimally invasive surgery is less traumatic and allows for rapid recovery, with a hospital stay of only 3-5 days.

Recommendations for International Patients

Do not panic: A ground-glass nodule is not necessarily lung cancer; most cases only require observation.

Use a consistent follow-up facility: Try to have follow-up at the same hospital for easier comparison. If seeking medical care abroad, be sure to bring previous imaging.

Communicate proactively: Ask your doctor about the size, solid component, and risk stratification of your nodule.

Consider remote consultation: If you have doubts about the local plan, you can consult thoracic surgery or radiology experts in Shanghai. Mei Jia Kang offers international remote consultation services, where professors from top-tier hospitals interpret imaging and develop personalized follow-up plans.

Adopt a healthy lifestyle: Quit smoking, avoid exposure to cooking fumes, and undergo annual low-dose CT screening.

Follow-up management is both a science and an exercise in patience. May every nodule carrier face it rationally and make decisions together with their doctors. If you have any questions, feel free to contact us for professional advice.